10-Q/A: IMAC Holdings Restates Q2 Financials Amid Business Pivot and Ongoing Liquidity Concerns

IMAC Holdings, Inc. has filed an amended quarterly report for Q2 2024, restating prior financials due to preferred dividend accounting errors, while continuing its strategic shift to precision cancer medicine despite significant liquidity challenges and ongoing regulatory audits.

Summary

• IMAC Holdings, Inc. filed an amended Quarterly Report on Form 10-Q/A for the quarter ended June 30, 2024, to restate previously issued financial statements due to an error in accounting for preferred dividends.
• The company's continuing operations are now focused on precision medicine in cancer treatment, specifically activated protein analysis for breast cancer clinical testing and collaborations with biopharmaceutical companies, following the acquisition of laboratory capabilities from Theralink Technologies, Inc.
• All previous patient care operations, including IMAC Regeneration Centers and The BackSpace retail stores, were sold or discontinued as of December 31, 2023, and are presented as discontinued operations.
• For the six months ended June 30, 2024, the company reported revenues of $15,750 from continuing operations, resulting in a gross loss of $56,252.
• Net loss from continuing operations for the six months ended June 30, 2024, was $1,862,005, an improvement from $2,455,760 in the same period of 2023.
• Net income from discontinued operations was $71,382 for the six months ended June 30, 2024, a significant improvement from a net loss of $2,646,200 in the prior year period.
• The overall net loss for the six months ended June 30, 2024, was $1,790,623, compared to $5,101,960 for the same period in 2023.
• Net loss available to common stockholders for the six months ended June 30, 2024, was $2,518,104, compared to $5,101,960 in the prior year period, impacted by $727,481 in preferred dividends.
• The company's cash balance increased to $890,610 as of June 30, 2024, from $221,511 at December 31, 2023.
• Working capital deficit worsened to ($3.3 million) as of June 30, 2024, from ($0.8 million) at December 31, 2023, primarily due to increased current liabilities of $3,993,207.
• The company raised $1.35 million from the sale of Series C-2, D, E, and F preferred stock and issued promissory notes for $1.4 million (aggregate purchase price $1 million) during the six months ended June 30, 2024.
• Subsequent to June 30, 2024, the company issued additional promissory notes for $840,000 (purchase price $600,000) and completed a PIPE Financing on November 14, 2024, raising $3,740,000 from the sale of Series G convertible preferred stock and warrants, with $2,240,000 used to repay outstanding promissory notes.
• The company has identified material weaknesses in its internal control over financial reporting, specifically insufficient accounting department resources and lack of segregation of duties.
• IMAC Holdings regained compliance with Nasdaq's Minimum Equity Rule on July 17, 2024, but remains under a one-year Panel Monitor.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by a worsening working capital deficit, substantial doubt about its going concern, and minimal revenue from its new core business. While it has successfully raised capital and reduced overall losses, the underlying operational and control weaknesses, coupled with significant contingent liabilities from past operations, indicate a high-risk profile. The strategic pivot is positive but very early stage and not yet proven.

Positives

• The company successfully pivoted its core business to precision medicine in cancer treatment, acquiring relevant laboratory capabilities and intellectual property licenses.
• Overall net loss significantly decreased to $1,790,623 for the six months ended June 30, 2024, from $5,101,960 in the prior year period.
• Net cash used in operating activities improved to $930,128 for the six months ended June 30, 2024, compared to $1,670,284 in the prior year period.
• Cash balance increased to $890,610 as of June 30, 2024, from $221,511 at December 31, 2023.
• Significant capital was raised through preferred stock issuances ($1.35 million) and promissory notes ($1 million purchase price) during the reporting period, and an additional $3.74 million in PIPE financing post-period, demonstrating access to funding.
• The company regained compliance with Nasdaq's Minimum Equity Rule on July 17, 2024, mitigating immediate delisting concerns.

Negatives

• The company's continuing operations generated minimal revenue of $15,750 and a gross loss of $56,252 for the six months ended June 30, 2024, indicating that the new business segment is not yet profitable.
• The company has a substantial doubt about its ability to continue as a going concern for the next twelve months.
• Working capital deficit significantly worsened to ($3.3 million) as of June 30, 2024, from ($0.8 million) at December 31, 2023, driven by a substantial increase in current liabilities.
• Total stockholders' deficit increased to ($1,769,724) as of June 30, 2024, from ($752,647) at December 31, 2023.
• The company incurred significant preferred dividends of $727,481 for the six months ended June 30, 2024, impacting net loss available to common stockholders.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting resources and lack of segregation of duties, which could lead to financial misstatements.
• Multiple ongoing CMS audits and legal proceedings related to discontinued operations pose significant contingent liabilities, with potential overpayments recommended totaling over $4 million across various locations (Progressive Health, Advantage Therapy, Ozzie Smith Center).

Risks

• Inability to obtain additional financing on favorable terms or at all, which could force delays, reductions, or termination of development and acquisition activities, potentially leading to cessation of operations.
• Challenges in successfully integrating the acquired assets from Theralink Technologies, Inc., and obtaining necessary credentials for Medicare and third-party payor reimbursement for the 'Ignite test', which could limit revenue generation.
• Difficulty in attracting and retaining competent, skilled laboratory and sales personnel for the new laboratory operations at acceptable costs.
• Failure to control operating expenses and prove the financial benefit of the Theralink asset acquisition to the company and stockholders.
• Susceptibility to investigations or audits by the Centers for Medicare & Medicaid Services (CMS), health insurance providers, and the IRS, which may result in reclaimed payments and adversely affect financial performance.
• Adverse financial impact from liabilities associated with discontinued operations, including potential criminal charges, substantial fines, and civil penalties from government investigations.
• Failure to achieve and sustain commercial success for the new precision medicine services due to factors like lack of acceptance by the medical community, competition, inadequate insurance coverage/reimbursement, or patient affordability issues.
• Intense competition in the cancer information field from companies with greater resources and faster product development, potentially rendering the company's technology obsolete.
• Inability to safeguard against security breaches in information systems, leading to potential misappropriation of confidential information, reputational damage, and significant costs.
• Exposure to potential product liability claims inherent in the research, development, manufacturing, and marketing of technology, with insurance coverage potentially inadequate or unavailable.
• Uncertainty and complex legal matters regarding licensed patents, including challenges to validity, enforceability, or scope, and the risk of infringement claims.
• Stock price volatility due to various factors, including operational results, analyst expectations, competitive announcements, regulatory developments, and future stock sales.
• Adverse effects on common stockholders from the issuance of preferred stock, which may have preferences over common stock regarding dividends or liquidation, and can dilute voting power.
• Potential delisting from Nasdaq if the company fails to continuously meet listing criteria, which would harm capital raising ability, liquidity, and market price.
• Regulatory changes, such as proposed government regulation of Laboratory Developed Tests (LDTs), could require additional clinical trials, increase costs, or delay/prevent necessary regulatory approvals.

Future Outlook

The company's future success depends on its ability to obtain additional financing, attract skilled laboratory and sales personnel, control operating expenses, and successfully integrate and commercialize the acquired Theralink assets. The technology is expected to be used for FDA approval of treatments and to determine patient benefits. The company anticipates needing to raise additional capital to fund future operations and may be forced to delay, limit, reduce, or terminate development or acquisition activities if funding is not available.

Management Comments

• Management, in concurrence with the Audit Committee, determined that previously issued financial statements for the period ended June 30, 2024, should no longer be relied upon and require restatement due to an error in accounting for preferred dividends.
• Management has determined that the company's financial condition raises substantial doubt as to its ability to continue as a going concern.
• Management anticipates expanding accounting functions with dedicated staff and improving internal accounting procedures and separation of duties when additional capital resources are available.

Industry Context

The company is undergoing a significant strategic shift from a traditional physical therapy and regenerative medicine clinic model to a precision medicine business focused on cancer treatment. This move aligns with a broader industry trend towards personalized healthcare and advanced diagnostics, particularly in oncology. However, the new business is in its early stages, with minimal revenue generated so far, indicating a challenging transition period. The competitive landscape in cancer information and predictive biomarkers is intense, with many established players and rapid technological advancements.

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or results to assess against industry standards. The company is undergoing a significant business model transition, making direct comparisons difficult without more detailed information on its new market segment.

Corporate Governance

Legal Proceedings

• The company is subject to audits under various governmental programs, including by the Center for Medicare & Medicaid Services (CMS), to identify potential improper payments.
• Covent Bridge Group, a CMS contractor, recommended an overpayment of $2,716,056.33 (statistical extrapolation of $6,791.33 from 38 claims) for Progressive Health & Rehabilitation, Ltd. for periods from July 2017 to November 2020. The company received a payment request for $2,709,265 in December 2021 and is appealing the decision.
• Covent Bridge Group recommended an overpayment of $492,086.22 (statistical extrapolation of $10,420.22 from a sample) related to Advantage Therapy. The company received a payment request for $481,666.00 in May 2022 and is appealing the decision. A recoupment balance of approximately $138,000 was fully reserved as of December 31, 2023.
• A payment suspension was issued by Covent Bridge Group for IMAC Regeneration Center of Kentucky in December 2022, resulting in a recoupment balance of approximately $90,000 fully reserved as of December 31, 2023. The company is complying with a Corrective Action Plan and appealing the findings.
• On November 22, 2024, the company received notification of an estimated overpayment of $1,096,346.51 for The Ozzie Smith Center (actual overpayment $8,284.51) for claims from February 26, 2020, through January 2, 2024. The company plans to appeal.
• The company and its subsidiary are in default in a foreclosure action regarding a lease for a former clinic location in Tampa, Florida. Discussions with the landlord are ongoing, and the likelihood or amount of potential loss cannot be estimated at this time.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing preferred stock and warrant issuances. The substantial doubt about going concern and material weaknesses in internal controls pose high investment risk. However, the strategic pivot and reduced overall net loss could be seen as long-term positives if successfully executed.
• **Employees**: The business model shift and closure of previous clinics likely impacted employees in discontinued operations. The new precision medicine business will require attracting and retaining skilled personnel.
• **Customers (Patients/Biopharmaceutical Companies)**: Patients seeking precision cancer medicine may benefit from the new services, assuming successful commercialization and reimbursement. Biopharmaceutical companies may benefit from collaborations for drug target identification and clinical trials.
• **Suppliers**: The company's financial instability and reliance on external funding could impact its ability to pay vendors, as indicated by $1.1 million in current liabilities owed to vendors.
• **Creditors**: Holders of preferred stock and promissory notes are significant creditors, and their rights are detailed in the filing. The company's going concern risk directly impacts their ability to recover investments.

Next Steps

• Obtain additional financing to fund projected costs associated with asset acquisition and personnel.
• Attract competent, skilled laboratory and sales personnel for the new laboratory operations.
• Control operating expenses and demonstrate the benefit of the Theralink asset acquisition.
• Obtain credentials for reimbursement of the 'Ignite test' by Medicare and third-party payors.
• Continue appeals processes for ongoing CMS audits related to Progressive Health & Rehabilitation, Ltd., Advantage Therapy, and The Ozzie Smith Center.
• Comply with the Corrective Action Plan recommended by Kepro for IMAC Regeneration Center of Kentucky and continue appeals.
• Resolve discussions with the landlord regarding outstanding amounts for the defaulted Tampa, Florida lease.
• Expand accounting functions with dedicated staff and improve internal accounting procedures and separation of duties to address material weaknesses in internal controls.

Key Dates

Recommendation

Keywords

Precision Medicine, Cancer Treatment, Activated Protein Analysis, SEC Filing, Restatement, Quarterly Report, Financial Performance, Liquidity, Going Concern, Preferred Stock, Promissory Notes, Capital Raise, Nasdaq Compliance, Internal Controls, CMS Audit, Discontinued Operations, Theralink Technologies, Biopharmaceutical Collaborations, Risk Factors